Richard Alan Rudick Purchases 87,300 Shares of Immunic, Inc. (NASDAQ:IMUX) Stock

Immunic, Inc. (NASDAQ:IMUX) Director Richard Alan Rudick acquired 87,300 shares of Immunic stock in a transaction that occurred on Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares in the company, valued at $100,395. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immunic Trading Up 1.3 %

IMUX traded up $0.02 during trading on Wednesday, hitting $1.17. 1,185,573 shares of the stock were exchanged, compared to its average volume of 616,367. The stock has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $1.35. Immunic, Inc. has a 1-year low of $0.97 and a 1-year high of $2.11.

Institutional Investors Weigh In On Immunic

A number of institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in Immunic in the first quarter valued at $25,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Ikarian Capital LLC grew its holdings in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares during the period. Vanguard Group Inc. raised its position in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares during the period. Finally, Janus Henderson Group PLC purchased a new stake in shares of Immunic during the 1st quarter worth about $9,266,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Wall Street Analysts Forecast Growth

IMUX has been the subject of several recent research reports. EF Hutton Acquisition Co. I raised Immunic to a “strong-buy” rating in a research report on Monday, September 16th. B. Riley began coverage on Immunic in a report on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price for the company. Piper Sandler restated an “overweight” rating and issued a $28.00 target price on shares of Immunic in a research note on Tuesday, July 16th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday. Finally, Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Immunic presently has an average rating of “Buy” and a consensus target price of $11.20.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.